Top Markets
#1 ADO Protocol ADO Protocol +329.37%
#2 GoPlus Security GoPlus Security +51.72%
#3 Nockchain Nockchain +48.66%
#4 Starpower Starpower +35.00%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +32.86%
#6 Tutorial Tutorial +32.59%
#7 The Black Bull The Black Bull +28.95%
#8 Fake World Assets Fake World Assets +25.07%
#9 GAIB AID GAIB AID +24.67%
#10 Verus Coin Verus Coin +20.20%
Coin of the day
ADO Protocol ADO Protocol
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
Classificação em ações #34046
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Preço da ação
$0.567
Valor de mercado
$6.34M
Variação (1 dia)
-24.96%
Variação (1 ano)
-57.37%
País
US
Negociar Citius Pharmaceuticals, Inc. (CTXR)

Categoria

Healthcare
Rácio P/S de Citius Pharmaceuticals, Inc. (CTXR)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Citius Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Citius Pharmaceuticals, Inc. de 2026 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE